1. HBW Insight
  2. >>Health
  3. >>Policy & Regulation
  4. >>Legal

Sunscreen SPFs Back In Plaintiffs’ Crosshairs? Alleged Supergoop Misrepresentations Don't Go Unseen

 
• By Ryan Nelson

Plaintiff Marceann Dunning says she and other consumers would not have purchased Supergoop Unseen Sunscreen for body and face, or would have paid less for them, had they known the products’ SPF was significantly lower than the SPF 40 labeled. A rash of similar class actions years back against major sunscreen brands fizzled, ostensibly in quiet settlements with lead plaintiffs.

Supergoop Unseen Sunscreen products for face and body are labeled as SPF 40, but their real SPF values are around half that, according to plaintiff Marceann Dunning’s complaint filed in the US District Court for New York’s Southern District on 28 December 2023.

Dunning says she conducted SPF testing of Supergoop Unseen and Supergoop Unseen Body in accordance with US Food and Drug Administration requirements and determined

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal

Supreme Court 1935 Ruling Limiting Executive Authority On Appointments ‘Unravels’ Today – DoJ

 
• By Malcolm Spicer

In complaint and response to motion to dismiss, Rebecca Kelly Slaughter’s and Alvaro Bedoya’s attorneys elaborate on Supreme Court ‘s 1935 decision, Humphrey’s Executor v. US. Administration attorneys, though, contend the ruling isn’t relevant to the current FTC.

Congress, Researchers Highlight Security Risks At DNA Testing Services

 
• By Elizabeth Orr

Congress launched an inquiry into 23andMe amid privacy concerns following its bankruptcy, particularly regarding the potential sale of sensitive user data. Additionally, a Cybernews report gave 40 DNA testing firms an average cybersecurity grade of D, citing widespread vulnerabilities and data breaches, along with inadequate public information about their security practices.

Xlear Sees Tip Of FTC Policy Iceberg In DoJ Dismissal Of False Advertising Complaint

 
• By Malcolm Spicer

It wasn’t a quick decision for Xlear to accept DoJ attorneys’ offer to dismiss the case. “I want the I want the FTC to change its policy and its behaviors,” says Xlear president Nathan Jones.

US FDA May Lose Some Autonomy Under HHS General Counsel Reorganization

 
• By Sarah Karlin-Smith

Health and Human Services Secretary Robert F. Kennedy Jr. is moving FDA Chief Counsel Robert Foster to a new senior position as Chief Counsel for Food, Research, and Drugs at HHS. Hilary Perkins will become FDA chief counsel.

More from Policy & Regulation

Over The Counter: Everything You Wanted To Know About Real World Evidence, With IQVIA’s Volker Spitzer

 
• By David Ridley

HBW Insight finds out all about real world evidence and its potential for the OTC industry by chatting with IQVIA Consumer Health's vice president of global research and development and real-world evidence services, Volker Spitzer.

US Tariffs Pose ‘Existential Threat’ To EU Medical Devices Industry

 
• By David Ridley

AESGP, MedTech Europe and other associations representing medtech companies including manufacturers of self-care devices call for such products to be included in European Commission proposals for “zero-for-zero” trade in industrial goods between Europe and the US.

Stakeholders Hope US FDA’s Proposed Animal Test Phase-Out For Drugs Will Extend To OTCs, Cosmetics

 
• By Eileen Francis and Lauren Nardella

The US Food and Drug Administration has released a roadmap to adopt new approach methodologies in lieu of animal testing for monoclonal antibody therapies and other drugs, which may include OTC drugs though the proposal does not specifically include cosmetics.